1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Restless Legs Syndrome Market Size Growth Rate by Type: 2017 VS 2021 VS 2028 1.2.2 Pharmacological Therapy 1.2.3 Non-Pharmacological Therapy 1.3 Market by End User 1.3.1 Global Restless Legs Syndrome Market Share by End User: 2017 VS 2021 VS 2028 1.3.2 Below 35 Years Old 1.3.3 From 35 to 50 Years Old 1.3.4 Above 50 Years Old 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global Restless Legs Syndrome Market Perspective (2017-2028) 2.2 Restless Legs Syndrome Growth Trends by Region 2.2.1 Restless Legs Syndrome Market Size by Region: 2017 VS 2021 VS 2028 2.2.2 Restless Legs Syndrome Historic Market Size by Region (2017-2022) 2.2.3 Restless Legs Syndrome Forecasted Market Size by Region (2023-2028) 2.3 Restless Legs Syndrome Market Dynamics 2.3.1 Restless Legs Syndrome Industry Trends 2.3.2 Restless Legs Syndrome Market Drivers 2.3.3 Restless Legs Syndrome Market Challenges 2.3.4 Restless Legs Syndrome Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Restless Legs Syndrome Players by Revenue 3.1.1 Global Top Restless Legs Syndrome Players by Revenue (2017-2022) 3.1.2 Global Restless Legs Syndrome Revenue Market Share by Players (2017-2022) 3.2 Global Restless Legs Syndrome Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.3 Players Covered: Ranking by Restless Legs Syndrome Revenue 3.4 Global Restless Legs Syndrome Market Concentration Ratio 3.4.1 Global Restless Legs Syndrome Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Restless Legs Syndrome Revenue in 2021 3.5 Restless Legs Syndrome Key Players Head office and Area Served 3.6 Key Players Restless Legs Syndrome Product Solution and Service 3.7 Date of Enter into Restless Legs Syndrome Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Restless Legs Syndrome Breakdown Data by Type 4.1 Global Restless Legs Syndrome Historic Market Size by Type (2017-2022) 4.2 Global Restless Legs Syndrome Forecasted Market Size by Type (2023-2028) 5 Restless Legs Syndrome Breakdown Data by End User 5.1 Global Restless Legs Syndrome Historic Market Size by End User (2017-2022) 5.2 Global Restless Legs Syndrome Forecasted Market Size by End User (2023-2028) 6 North America 6.1 North America Restless Legs Syndrome Market Size (2017-2028) 6.2 North America Restless Legs Syndrome Market Size by Country (2017-2022) 6.3 North America Restless Legs Syndrome Market Size by Country (2023-2028) 6.4 United States 6.5 Canada 7 Europe 7.1 Europe Restless Legs Syndrome Market Size (2017-2028) 7.2 Europe Restless Legs Syndrome Market Size by Country (2017-2022) 7.3 Europe Restless Legs Syndrome Market Size by Country (2023-2028) 7.4 Germany 7.5 France 7.6 U.K. 7.7 Italy 7.8 Russia 7.9 Nordic Countries 8 Asia-Pacific 8.1 Asia-Pacific Restless Legs Syndrome Market Size (2017-2028) 8.2 Asia-Pacific Restless Legs Syndrome Market Size by Country (2017-2022) 8.3 Asia-Pacific Restless Legs Syndrome Market Size by Country (2023-2028) 8.4 China 8.5 Japan 8.6 South Korea 8.7 Southeast Asia 8.8 India 8.9 Australia 9 Latin America 9.1 Latin America Restless Legs Syndrome Market Size (2017-2028) 9.2 Latin America Restless Legs Syndrome Market Size by Country (2017-2022) 9.3 Latin America Restless Legs Syndrome Market Size by Country (2023-2028) 9.4 Mexico 9.5 Brazil 10 Middle East & Africa 10.1 Middle East & Africa Restless Legs Syndrome Market Size (2017-2028) 10.2 Middle East & Africa Restless Legs Syndrome Market Size by Country (2017-2022) 10.3 Middle East & Africa Restless Legs Syndrome Market Size by Country (2023-2028) 10.4 Turkey 10.5 Saudi Arabia 10.6 UAE 11 Key Players Profiles 11.1 Boehringer Ingelheim GmbH 11.1.1 Boehringer Ingelheim GmbH Company Detail 11.1.2 Boehringer Ingelheim GmbH Business Overview 11.1.3 Boehringer Ingelheim GmbH Restless Legs Syndrome Introduction 11.1.4 Boehringer Ingelheim GmbH Revenue in Restless Legs Syndrome Business (2017-2022) 11.1.5 Boehringer Ingelheim GmbH Recent Development 11.2 UCB SA 11.2.1 UCB SA Company Detail 11.2.2 UCB SA Business Overview 11.2.3 UCB SA Restless Legs Syndrome Introduction 11.2.4 UCB SA Revenue in Restless Legs Syndrome Business (2017-2022) 11.2.5 UCB SA Recent Development 11.3 Astellas 11.3.1 Astellas Company Detail 11.3.2 Astellas Business Overview 11.3.3 Astellas Restless Legs Syndrome Introduction 11.3.4 Astellas Revenue in Restless Legs Syndrome Business (2017-2022) 11.3.5 Astellas Recent Development 11.4 Arbor Pharmaceuticals 11.4.1 Arbor Pharmaceuticals Company Detail 11.4.2 Arbor Pharmaceuticals Business Overview 11.4.3 Arbor Pharmaceuticals Restless Legs Syndrome Introduction 11.4.4 Arbor Pharmaceuticals Revenue in Restless Legs Syndrome Business (2017-2022) 11.4.5 Arbor Pharmaceuticals Recent Development 11.5 GlaxoSmithKline plc. 11.5.1 GlaxoSmithKline plc. Company Detail 11.5.2 GlaxoSmithKline plc. Business Overview 11.5.3 GlaxoSmithKline plc. Restless Legs Syndrome Introduction 11.5.4 GlaxoSmithKline plc. Revenue in Restless Legs Syndrome Business (2017-2022) 11.5.5 GlaxoSmithKline plc. Recent Development 11.6 Ligand Pharmaceuticals Incorporated 11.6.1 Ligand Pharmaceuticals Incorporated Company Detail 11.6.2 Ligand Pharmaceuticals Incorporated Business Overview 11.6.3 Ligand Pharmaceuticals Incorporated Restless Legs Syndrome Introduction 11.6.4 Ligand Pharmaceuticals Incorporated Revenue in Restless Legs Syndrome Business (2017-2022) 11.6.5 Ligand Pharmaceuticals Incorporated Recent Development 11.7 axxonis Pharma AG 11.7.1 axxonis Pharma AG Company Detail 11.7.2 axxonis Pharma AG Business Overview 11.7.3 axxonis Pharma AG Restless Legs Syndrome Introduction 11.7.4 axxonis Pharma AG Revenue in Restless Legs Syndrome Business (2017-2022) 11.7.5 axxonis Pharma AG Recent Development 11.8 Kyowa Hakko Kirin Co. 11.8.1 Kyowa Hakko Kirin Co. Company Detail 11.8.2 Kyowa Hakko Kirin Co. Business Overview 11.8.3 Kyowa Hakko Kirin Co. Restless Legs Syndrome Introduction 11.8.4 Kyowa Hakko Kirin Co. Revenue in Restless Legs Syndrome Business (2017-2022) 11.8.5 Kyowa Hakko Kirin Co. Recent Development 11.9 Jazz Pharmaceuticals, Inc. 11.9.1 Jazz Pharmaceuticals, Inc. Company Detail 11.9.2 Jazz Pharmaceuticals, Inc. Business Overview 11.9.3 Jazz Pharmaceuticals, Inc. Restless Legs Syndrome Introduction 11.9.4 Jazz Pharmaceuticals, Inc. Revenue in Restless Legs Syndrome Business (2017-2022) 11.9.5 Jazz Pharmaceuticals, Inc. Recent Development 11.10 Omeros Corporation 11.10.1 Omeros Corporation Company Detail 11.10.2 Omeros Corporation Business Overview 11.10.3 Omeros Corporation Restless Legs Syndrome Introduction 11.10.4 Omeros Corporation Revenue in Restless Legs Syndrome Business (2017-2022) 11.10.5 Omeros Corporation Recent Development 11.11 Manhattan Pharmaceuticals 11.11.1 Manhattan Pharmaceuticals Company Detail 11.11.2 Manhattan Pharmaceuticals Business Overview 11.11.3 Manhattan Pharmaceuticals Restless Legs Syndrome Introduction 11.11.4 Manhattan Pharmaceuticals Revenue in Restless Legs Syndrome Business (2017-2022) 11.11.5 Manhattan Pharmaceuticals Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details

List of Tables Table 1. Global Restless Legs Syndrome Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028 Table 2. Key Players of Pharmacological Therapy Table 3. Key Players of Non-Pharmacological Therapy Table 4. Global Restless Legs Syndrome Market Size Growth by End User (US$ Million): 2017 VS 2021 VS 2028 Table 5. Global Restless Legs Syndrome Market Size by Region (US$ Million): 2017 VS 2021 VS 2028 Table 6. Global Restless Legs Syndrome Market Size by Region (2017-2022) & (US$ Million) Table 7. Global Restless Legs Syndrome Market Share by Region (2017-2022) Table 8. Global Restless Legs Syndrome Forecasted Market Size by Region (2023-2028) & (US$ Million) Table 9. Global Restless Legs Syndrome Market Share by Region (2023-2028) Table 10. Restless Legs Syndrome Market Trends Table 11. Restless Legs Syndrome Market Drivers Table 12. Restless Legs Syndrome Market Challenges Table 13. Restless Legs Syndrome Market Restraints Table 14. Global Restless Legs Syndrome Revenue by Players (2017-2022) & (US$ Million) Table 15. Global Restless Legs Syndrome Market Share by Players (2017-2022) Table 16. Global Top Restless Legs Syndrome Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Restless Legs Syndrome as of 2021) Table 17. Ranking of Global Top Restless Legs Syndrome Companies by Revenue (US$ Million) in 2021 Table 18. Global 5 Largest Players Market Share by Restless Legs Syndrome Revenue (CR5 and HHI) & (2017-2022) Table 19. Key Players Headquarters and Area Served Table 20. Key Players Restless Legs Syndrome Product Solution and Service Table 21. Date of Enter into Restless Legs Syndrome Market Table 22. Mergers & Acquisitions, Expansion Plans Table 23. Global Restless Legs Syndrome Market Size by Type (2017-2022) & (US$ Million) Table 24. Global Restless Legs Syndrome Revenue Market Share by Type (2017-2022) Table 25. Global Restless Legs Syndrome Forecasted Market Size by Type (2023-2028) & (US$ Million) Table 26. Global Restless Legs Syndrome Revenue Market Share by Type (2023-2028) Table 27. Global Restless Legs Syndrome Market Size by End User (2017-2022) & (US$ Million) Table 28. Global Restless Legs Syndrome Revenue Market Share by End User (2017-2022) Table 29. Global Restless Legs Syndrome Forecasted Market Size by End User (2023-2028) & (US$ Million) Table 30. Global Restless Legs Syndrome Revenue Market Share by End User (2023-2028) Table 31. North America Restless Legs Syndrome Market Size by Country (2017-2022) & (US$ Million) Table 32. North America Restless Legs Syndrome Market Size by Country (2023-2028) & (US$ Million) Table 33. Europe Restless Legs Syndrome Market Size by Country (2017-2022) & (US$ Million) Table 34. Europe Restless Legs Syndrome Market Size by Country (2023-2028) & (US$ Million) Table 35. Asia-Pacific Restless Legs Syndrome Market Size by Region (2017-2022) & (US$ Million) Table 36. Asia-Pacific Restless Legs Syndrome Market Size by Region (2023-2028) & (US$ Million) Table 37. Latin America Restless Legs Syndrome Market Size by Country (2017-2022) & (US$ Million) Table 38. Latin America Restless Legs Syndrome Market Size by Country (2023-2028) & (US$ Million) Table 39. Middle East & Africa Restless Legs Syndrome Market Size by Country (2017-2022) & (US$ Million) Table 40. Middle East & Africa Restless Legs Syndrome Market Size by Country (2023-2028) & (US$ Million) Table 41. Boehringer Ingelheim GmbH Company Detail Table 42. Boehringer Ingelheim GmbH Business Overview Table 43. Boehringer Ingelheim GmbH Restless Legs Syndrome Product Table 44. Boehringer Ingelheim GmbH Revenue in Restless Legs Syndrome Business (2017-2022) & (US$ Million) Table 45. Boehringer Ingelheim GmbH Recent Development Table 46. UCB SA Company Detail Table 47. UCB SA Business Overview Table 48. UCB SA Restless Legs Syndrome Product Table 49. UCB SA Revenue in Restless Legs Syndrome Business (2017-2022) & (US$ Million) Table 50. UCB SA Recent Development Table 51. Astellas Company Detail Table 52. Astellas Business Overview Table 53. Astellas Restless Legs Syndrome Product Table 54. Astellas Revenue in Restless Legs Syndrome Business (2017-2022) & (US$ Million) Table 55. Astellas Recent Development Table 56. Arbor Pharmaceuticals Company Detail Table 57. Arbor Pharmaceuticals Business Overview Table 58. Arbor Pharmaceuticals Restless Legs Syndrome Product Table 59. Arbor Pharmaceuticals Revenue in Restless Legs Syndrome Business (2017-2022) & (US$ Million) Table 60. Arbor Pharmaceuticals Recent Development Table 61. GlaxoSmithKline plc. Company Detail Table 62. GlaxoSmithKline plc. Business Overview Table 63. GlaxoSmithKline plc. Restless Legs Syndrome Product Table 64. GlaxoSmithKline plc. Revenue in Restless Legs Syndrome Business (2017-2022) & (US$ Million) Table 65. GlaxoSmithKline plc. Recent Development Table 66. Ligand Pharmaceuticals Incorporated Company Detail Table 67. Ligand Pharmaceuticals Incorporated Business Overview Table 68. Ligand Pharmaceuticals Incorporated Restless Legs Syndrome Product Table 69. Ligand Pharmaceuticals Incorporated Revenue in Restless Legs Syndrome Business (2017-2022) & (US$ Million) Table 70. Ligand Pharmaceuticals Incorporated Recent Development Table 71. axxonis Pharma AG Company Detail Table 72. axxonis Pharma AG Business Overview Table 73. axxonis Pharma AG Restless Legs Syndrome Product Table 74. axxonis Pharma AG Revenue in Restless Legs Syndrome Business (2017-2022) & (US$ Million) Table 75. axxonis Pharma AG Recent Development Table 76. Kyowa Hakko Kirin Co. Company Detail Table 77. Kyowa Hakko Kirin Co. Business Overview Table 78. Kyowa Hakko Kirin Co. Restless Legs Syndrome Product Table 79. Kyowa Hakko Kirin Co. Revenue in Restless Legs Syndrome Business (2017-2022) & (US$ Million) Table 80. Kyowa Hakko Kirin Co. Recent Development Table 81. Jazz Pharmaceuticals, Inc. Company Detail Table 82. Jazz Pharmaceuticals, Inc. Business Overview Table 83. Jazz Pharmaceuticals, Inc. Restless Legs Syndrome Product Table 84. Jazz Pharmaceuticals, Inc. Revenue in Restless Legs Syndrome Business (2017-2022) & (US$ Million) Table 85. Jazz Pharmaceuticals, Inc. Recent Development Table 86. Omeros Corporation Company Detail Table 87. Omeros Corporation Business Overview Table 88. Omeros Corporation Restless Legs Syndrome Product Table 89. Omeros Corporation Revenue in Restless Legs Syndrome Business (2017-2022) & (US$ Million) Table 90. Omeros Corporation Recent Development Table 91. Manhattan Pharmaceuticals Company Detail Table 92. Manhattan Pharmaceuticals Business Overview Table 93. Manhattan Pharmaceuticals Restless Legs SyndromeProduct Table 94. Manhattan Pharmaceuticals Revenue in Restless Legs Syndrome Business (2017-2022) & (US$ Million) Table 95. Manhattan Pharmaceuticals Recent Development Table 96. Research Programs/Design for This Report Table 97. Key Data Information from Secondary Sources Table 98. Key Data Information from Primary Sources List of Figures Figure 1. Global Restless Legs Syndrome Market Share by Type: 2021 VS 2028 Figure 2. Pharmacological Therapy Features Figure 3. Non-Pharmacological Therapy Features Figure 4. Global Restless Legs Syndrome Market Share by End User in 2021 & 2028 Figure 5. Below 35 Years Old Case Studies Figure 6. From 35 to 50 Years Old Case Studies Figure 7. Above 50 Years Old Case Studies Figure 8. Restless Legs Syndrome Report Years Considered Figure 9. Global Restless Legs Syndrome Market Size (US$ Million), Year-over-Year: 2017-2028 Figure 10. Global Restless Legs Syndrome Market Size, (US$ Million), 2017 VS 2021 VS 2028 Figure 11. Global Restless Legs Syndrome Market Share by Region: 2021 VS 2028 Figure 12. Global Restless Legs Syndrome Market Share by Players in 2021 Figure 13. Global Top Restless Legs Syndrome Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Restless Legs Syndrome as of 2021) Figure 14. The Top 10 and 5 Players Market Share by Restless Legs Syndrome Revenue in 2021 Figure 15. North America Restless Legs Syndrome Market Size YoY Growth (2017-2028) & (US$ Million) Figure 16. North America Restless Legs Syndrome Market Share by Country (2017-2028) Figure 17. United States Restless Legs Syndrome Market Size YoY Growth (2017-2028) & (US$ Million) Figure 18. Canada Restless Legs Syndrome Market Size YoY Growth (2017-2028) & (US$ Million) Figure 19. Europe Restless Legs Syndrome Market Size YoY Growth (2017-2028) & (US$ Million) Figure 20. Europe Restless Legs Syndrome Market Share by Country (2017-2028) Figure 21. Germany Restless Legs Syndrome Market Size YoY Growth (2017-2028) & (US$ Million) Figure 22. France Restless Legs Syndrome Market Size YoY Growth (2017-2028) & (US$ Million) Figure 23. U.K. Restless Legs Syndrome Market Size YoY Growth (2017-2028) & (US$ Million) Figure 24. Italy Restless Legs Syndrome Market Size YoY Growth (2017-2028) & (US$ Million) Figure 25. Russia Restless Legs Syndrome Market Size YoY Growth (2017-2028) & (US$ Million) Figure 26. Nordic Countries Restless Legs Syndrome Market Size YoY Growth (2017-2028) & (US$ Million) Figure 27. Asia-Pacific Restless Legs Syndrome Market Size YoY Growth (2017-2028) & (US$ Million) Figure 28. Asia-Pacific Restless Legs Syndrome Market Share by Region (2017-2028) Figure 29. China Restless Legs Syndrome Market Size YoY Growth (2017-2028) & (US$ Million) Figure 30. Japan Restless Legs Syndrome Market Size YoY Growth (2017-2028) & (US$ Million) Figure 31. South Korea Restless Legs Syndrome Market Size YoY Growth (2017-2028) & (US$ Million) Figure 32. Southeast Asia Restless Legs Syndrome Market Size YoY Growth (2017-2028) & (US$ Million) Figure 33. India Restless Legs Syndrome Market Size YoY Growth (2017-2028) & (US$ Million) Figure 34. Australia Restless Legs Syndrome Market Size YoY Growth (2017-2028) & (US$ Million) Figure 35. Latin America Restless Legs Syndrome Market Size YoY Growth (2017-2028) & (US$ Million) Figure 36. Latin America Restless Legs Syndrome Market Share by Country (2017-2028) Figure 37. Mexico Restless Legs Syndrome Market Size YoY Growth (2017-2028) & (US$ Million) Figure 38. Brazil Restless Legs Syndrome Market Size YoY Growth (2017-2028) & (US$ Million) Figure 39. Middle East & Africa Restless Legs Syndrome Market Size YoY Growth (2017-2028) & (US$ Million) Figure 40. Middle East & Africa Restless Legs Syndrome Market Share by Country (2017-2028) Figure 41. Turkey Restless Legs Syndrome Market Size YoY Growth (2017-2028) & (US$ Million) Figure 42. Saudi Arabia Restless Legs Syndrome Market Size YoY Growth (2017-2028) & (US$ Million) Figure 43. Boehringer Ingelheim GmbH Revenue Growth Rate in Restless Legs Syndrome Business (2017-2022) Figure 44. UCB SA Revenue Growth Rate in Restless Legs Syndrome Business (2017-2022) Figure 45. Astellas Revenue Growth Rate in Restless Legs Syndrome Business (2017-2022) Figure 46. Arbor Pharmaceuticals Revenue Growth Rate in Restless Legs Syndrome Business (2017-2022) Figure 47. GlaxoSmithKline plc. Revenue Growth Rate in Restless Legs Syndrome Business (2017-2022) Figure 48. Ligand Pharmaceuticals Incorporated Revenue Growth Rate in Restless Legs Syndrome Business (2017-2022) Figure 49. axxonis Pharma AG Revenue Growth Rate in Restless Legs Syndrome Business (2017-2022) Figure 50. Kyowa Hakko Kirin Co. Revenue Growth Rate in Restless Legs Syndrome Business (2017-2022) Figure 51. Jazz Pharmaceuticals, Inc. Revenue Growth Rate in Restless Legs Syndrome Business (2017-2022) Figure 52. Omeros Corporation Revenue Growth Rate in Restless Legs Syndrome Business (2017-2022) Figure 53. Manhattan Pharmaceuticals Revenue Growth Rate in Restless Legs Syndrome Business (2017-2022) Figure 54. Bottom-up and Top-down Approaches for This Report Figure 55. Data Triangulation Figure 56. Key Executives Interviewed

Boehringer Ingelheim GmbH UCB SA Astellas Arbor Pharmaceuticals GlaxoSmithKline plc. Ligand Pharmaceuticals Incorporated axxonis Pharma AG Kyowa Hakko Kirin Co. Jazz Pharmaceuticals, Inc. Omeros Corporation Manhattan Pharmaceuticals